Hubei Bio-pharmaceutical Industrial Technological Institute Inc.
Clinical trials sponsored by Hubei Bio-pharmaceutical Industrial Technological Institute Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New ointment could zap Sun-Damaged skin lesions Results expected Dec 2026 (estimated)
- Healthy volunteers to test experimental lung disease drug Results expected Dec 2026 (estimated)
- New IPF drug candidate enters first human safety trial Results expected Jan 2027 (estimated)
- Can a new oral drug pass its first safety test in humans? Results expected May 2027 (estimated)
-
New ointment could zap Sun-Damaged skin lesions
Disease control Not yet recruitingThis study tests an ointment called HW211026 in 80 adults with actinic keratosis, rough skin patches caused by sun damage. The goal is to see if the ointment can completely clear these lesions on the face. Participants will use the ointment and be monitored for safety and effecti…
Phase 2 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New IPF drug candidate enters first human safety trial
Disease control Not yet recruitingThis early-stage trial tests a new tablet called HW241045 in 102 healthy volunteers to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a lung-scarring disease. The study is randomized, double-blind, and placebo-contr…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill aims to silence stubborn coughs
Symptom relief Not yet recruitingThis study tests an experimental drug called HW091077 for people with a chronic cough that lasts a year or more and doesn't improve with standard treatment. About 180 adults in China will receive either the drug or a placebo daily for 4 weeks. Researchers will measure cough frequ…
Phase 2 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Healthy volunteers to test experimental lung disease drug
Knowledge-focused Not yet recruitingThis early-stage study tests a new drug, HW252001, in 98 healthy adults aged 18 to 55. The goal is to check the drug's safety and how the body processes it, not to treat any disease. Participants will receive either the drug or a placebo, and researchers will monitor for side eff…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC